Blog

Aug 22, 2023

‘Extraordinary’ data reported for AstraZeneca lung cancer drug

By Angus Chen and Matthew Herper June 4, 2023 CHICAGO — Giving the AstraZeneca

By Angus Chen and Matthew Herper June 4, 2023

CHICAGO — Giving the AstraZeneca drug Tagrisso to patients with non-small cell lung cancer who have had their tumors removed reduced the risk of death by 51%, researchers said Sunday.

Put another way, that would mean that about one in 10 patients who received the drug would live another five years. "I expected we’d see something, but I was getting a little anxious," said Roy Herbst, the deputy director of the Yale Cancer Center and the lead author of the study. "The naysayers and funding bodies and so forth had said, ‘Where's the survival?’ Now, with the overall survival data, it was extraordinary."

advertisement

The results of the ADAURA trial were presented here at the annual meeting of the American Society of Clinical Oncology and published in the New England Journal of Medicine.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

Cancer Reporter

Angus Chen is a cancer reporter at STAT.

Senior Writer, Medicine, Editorial Director of Events

Matthew Herper covers medical innovation — both its promise and its perils.

ASCO23

cancer

drug development

pharmaceuticals

STAT+

This name will appear with your comment

There was an error saving your display name. Please check and try again.